Genetic markers in breast cancer – how far fave we come from BRCA1?

QR Code

Genetic markers in breast cancer – how far fave we come from BRCA1?

Breast cancer is the most common malignancy that develops in women worldwide, its incidence continues to rise and it is responsible for the highest death rates. Breast cancer can be classified as sporadic or familial – the strongest risk factor today is a family history. Germline mutations in high...

Full description

Bibliographic Details
Main Authors:	Avery-Kiejda, Kelly A., Wong, Michelle W., Scott, Rodney J.
Format:	Article
Language:	English
Published:	UKM Medical Molecular biology Institute, UMBI 2011
Online Access:	http://journalarticle.ukm.my/3061/ http://journalarticle.ukm.my/3061/1/2011-1-3.pdf

Similar Items

Genetic markers in breast cancer- How far have we come from BRCA1?
by: Avery-Kiejda KA,, et al.
Published: (2011)

Producing transgenic rice with improved traits and yield – how far have we come?
by: Wong, Clement Kiing Fook, et al.
Published: (2017)

BRCA1, BRCA2 mutations and the association with the clinicopathological characteristics of women with early-onset breast cancer
by: Ghazali, Mohamad Bazli
Published: (2014)

Low level of BRCA-1 mutations in Malaysian breast cancer patients
by: f, Salih, et al.
Published: (2010)

Asymptomatic microscopic haematuria: how far we need to investigate
by: Ab Rashid, Islah Munjih
Published: (2014)

Developing students' mathematical thinking: how far have we came?
by: Md. Yunus, Aida Suraya
Published: (2015)

Germany, here we come!
by: New Sunday Times,
Published: (2007)

Paris, here we come!
by: New Sunday Times,
Published: (2013)

Glucose and breast cancer 1 (BRCA1) biosensor based on zinc oxide nanostructures / Nur Azimah Mansor
by: Mansor, Nur Azimah
Published: (2016)

The Cost-Utility of Magnetic Resonance Imaging for Breast Cancer in BRCA1 Mutation Carriers Aged 30–49
by: Norman, Richard, et al.
Published: (2007)

Mutation detection of BRCA1 gene from Malaysian breast cancer patients by denaturing high performance liquid chromatography (DHPLC)
by: Mohamad Salih, Falah A., et al.
Published: (2009)

Metallointercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition
by: Yusoh, Nur Aininie, et al.
Published: (2020)

A short history of SLA: Where have we come from and where are we going?
by: Ellis, Rod
Published: (2020)

Far apart but close at heart
by: Tam, Michelle
Published: (2017)

Iron and virulence in Stenotrophomonas maltophilia: all we know so far
by: V., Kalidasan, et al.
Published: (2018)

Laboratory diagnostics in COVID-19: what we know so far
by: Zakariah, Siti Zulaikha, et al.
Published: (2020)

Heart Coming Home
by: Johnston, Michelle, et al.
Published: (2018)

Translation termination mutations analysis using the protein truncation test on exon11A of the BRCA1 gene in female breast cancer patients of Pahang, Malaysia
by: Alattraqchi, Ahmed G., et al.
Published: (2012)

Translation termination mutations naalysis using the protein truncation test on Exon11A of the BRCA1 gene in female breast cancer patients of Pahang, Malaysia
by: Alattraqchi, Ahmed Ghazi, et al.
Published: (2012)

Regional Economic Integration in ASEAN: How far will it go?
by: Kabir, Shahriar, et al.
Published: (2014)

Commentary: Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers
by: Glassey, R., et al.
Published: (2017)

Oral corective fedback in L2 clasroms: What We Know so Far
by: Ellis, Rod
Published: (2017)

Plastic obsession among Malaysian tourists: how far is it true?
by: Md Zaliki, Najiyah, et al.
Published: (2019)

How far the ecowarrior will go : an ecofeminist reading of Disney’s Moana
by: Mala Hernawati,
Published: (2021)

How does the use of Complementary Therapies contribute to the experience of patients with breast cancer?
by: Perkins, Katy Michelle
Published: (2013)

Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014
by: Chen, Zhuo, et al.
Published: (2017)

Should we bother doing dengue vector surveillance, and if so, how should we do it?
by: Williams, Craig R., et al.
Published: (2019)

Assessment of potential risk factors and skin ultrasound presentation associated with breast cancer-related lymphedema in long-term breast cancer survivors
by: Md Yusof, Khairunnisa’, et al.
Published: (2021)

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
by: Shafee, Norazizah, et al.
Published: (2008)

The Pilbara: From the Deserts Profits Come
by: Fitzgerald, Scott
Published: (2018)

Good work, poor work? We need to go far beyond capitalism to answer this question
by: Andrei, Daniela, et al.
Published: (2019)

PET-MRI imaging of cellular trafficking of lipid metabolism and its association with inflammatory and genetic markers in breast cancer
by: Shaharuddin, Shazreen, et al.
Published: (2018)

How far are we from solving the 2D & 3D face alignment problem? (and a dataset of 230,000 3D facial landmarks)
by: Bulat, Adrian, et al.
Published: (2017)

Sexual harassment: how far does the penal code protect the victim?
by: Anita Abdul Rahim,
Published: (2000)

Expression of autophagy and mitophagy markers in breast cancer tissues
by: Mustafa, Mohd Fazirul, et al.
Published: (2021)

Disaster risk index: How far should it take account of local attributes?
by: Islam, M., et al.
Published: (2013)

Dealing with lung cancer complications: how aggressive can we be?
by: How, Soon Hin
Published: (2013)

In vivo effects of sirolimus and sunitinib of breast cancer prognostic markers
by: Jaffar, Nurul Fathiyatul Nabila
Published: (2020)

Weak interlinkages between SMEs and Non-SMEs in Malaysia and Thailand: what do we know so far?
by: Utit, Chakrin, et al.
Published: (2022)

How come they know? The Effects of Social Comparison on Value Consciousness and Price Mavenism
by: Pillai, Kishore Gopalakrishna, et al.
Published: (2025)